After years of stagnation, treatments for Alzheimer's are experiencing a revival.
, which included 1,182 participants, slowed their rate of decline by 35 percent over 18 months. Lilly said it planned to submit the results for publication in a peer-reviewed journal.
"This does surpass what we've seen in the field to date," Brooks added."Less progression means more time for patients."In the trial, nearly half of patients who got donanemab saw no worsening of their Alzheimer's symptoms after a year of treatment, while 71 percent of patients who got the placebo saw their disease advance.
Patients and their physicians will have to weigh the drug's benefits against some serious side effects. Taking the drug can lead to cases of swelling or other abnormalities in the brain, the trial found. While most cases aren't serious, Lilly said at least two deaths were linked to these side effects.
Leqembi, on the other hand, is intended to be given for a longer period of time. Both are given by IV, with donanemab administered every four weeks and Leqembi every two weeks.Clinicians and analysts will most likely pore over the data on Leqembi and donanemab to suss out the advantages and disadvantages of each drug. Leqembi slowed the rate of cognitive decline in Alzheimer's patients by 27 percent over 18 months in a.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Read more »
Study: Experimental Alzheimer’s drug slows declineStudy: Experimental Alzheimer’s drug slows decline.
Read more »
Eli Lilly says experimental drug slows Alzheimer's worseningEli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease
Read more »
New Trial Data Is Strongest Yet for Any Experimental Alzheimer's DrugEli Lilly's drug donanemab appeared to slow down the rate of cognitive decline in patients by 35% compared to placebo.
Read more »
Experimental Alzheimer's drug slows cognitive declines in large trial, drugmaker Eli Lilly says | CNNAn experimental Alzheimer's medication slowed declines in patients' ability to think clearly and perform daily tasks by more than a third in a large clinical trial, drugmaker Eli Lilly said Wednesday.
Read more »
Eli Lilly says its experimental Alzheimer's drug appears to slow symptomsEli Lilly said its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease.
Read more »